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Key clinical message
Adverse effects of amiodarone are rarely seen in pediatric patients, but may
occur if amiodarone is applied for long-term treatment. Two rather rare phe-
nomena are blue-gray skin pigmentation and pulmonary mass. They represent
important differential diagnoses from more common clinical complications like
pneumonia and drug-induced toxic skin lesions.
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Introduction
Amiodarone is a widely used and highly effective drug in
the treatment of various atrial and ventricular arrhythmias.
Severe adverse effects are well known especially in the long-
term treatment. Atrial arrhythmias are a frequently
encountered clinical challenge in patients with congenital
heart disease. Currently, some of these patients may
undergo electrophysiologic study with radiofrequency abla-
tion. Yet, drug treatment is still an important treatment
option in this group of patients. Actual guidelines provide
the clinician with several treatment options of which amio-
darone is one of the most effective, although with the cost
of a wide range of adverse effects [1]. To the authors
knowledge this is the first description reporting an amio-
darone-induced blue-gray skin pigmentation and pul-
monary mass in a child. CASE: A 13-year-old male patient,
weighing 31.7 kg, with congenital Ebstein’s anomaly was
referred to our center for cardiac surgery. The patient‘s his-
tory included a primary univentricular approach with
Glenn anastomosis at the age of 10 months, tricuspid valve
reconstruction and implantation of a transvenous pace-
maker for sick sinus syndrome at the age of 6 years. Due to
atrial flutter he was treated with amiodarone (6 mg/kg/
day) since the age of 7 years. At the time of admission the
patient was in NYHA class III due to congestive heart fail-
ure without any pulmonary symptoms. Most strikingly he
presented with a blue-gray facial skin pigmentation
(Fig. 1). In addition, preoperative X-ray revealed several
ominous pulmonary nodules. A computed tomography
was performed (Fig. 2) and the suspicion of an abscess
forming pneumonia aroused. Yet, blood chemistry was
unremarkable and the patient showed no signs of an infec-
tion. Reviewing literature these findings were associated
with chronic amiodarone intake. Bronchoscopy was per-
formed which showed numerous marcrophages with foamy
cytoplasm, presumably in the context of lipid sediment,
and confirmed the diagnosis. Remarkably, no risk factors
were identified in the child that could have predisposed to
his condition. Amiodarone was discontinued after success-
276 ª 2016 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
ful cardiac surgery with tricuspid valve reconstruction,
right atrial reduction plastic, MAZE procedure, removal of
the transvenous pacemaker system and implantation of an
epimyocardial pacing system. Postoperative course was
uneventful. Follow-up after 1 year showed a thorough dis-
appearance of the blue-gray skin pigmentation and absence
of atrial arrhythmia. Noteworthy, the pulmonary nodules
showed only incomplete regression after 2 years follow-up.
Discussion
Amiodarone is one of the most effective and commonly
used drugs available for treatment of cardiac arrhythmias
in the adult and pediatric population. It prolongs the car-
diac repolarization through the sodium and calcium chan-
nel block and nonselective b-adrenergic inhibition. It has a
long plasma half-life of about 57 days and is hepatically
metabolized [2]. Many adverse effects are reported, espe-
cially in the long-term treatment. Apart from frequent
adverse effects like corneal microdeposits, reported in up
to 90% of patients, and photosensitivity (25–75%), blue-
gray skin discoloration (4–9%), and pulmonary toxicity
(1–17%) are rather rare [3]. The incidence of blue-gray
skin discoloration in children is estimated <2% [4].
Amiodarone-induced blue-gray skin pigmentation is
most often reported to occur following long-term treat-
ment in elderly patients with a predominance of male
patients. The exact pathomechanism of blue-gray skin
syndrome is still controversial. Several different theories
are discussed in literature. These include drug-induced
lipidosis, photosensitivity reaction to ultraviolet light, or
leukocytoclastic vasculitis [5]. The typical feature of the
blue-gray skin syndrome is the strictly facial skin pigmen-
tation. It is speculated that ultraviolet light induces amio-
darone and its metabolites to attach to the blood vessel
walls and the perivascular tissue. This is associated with
local vasodilatation and increased diffusion of amio-
darone and its metabolites, resulting in chronic tissue
accumulation. Therefore, only sun exposed regions are
affected [6]. Molecular mechanisms have been described
by Morissette et al. [7] who analyzed skin biopsies of
patients with blue-gray skin syndrome and concluded that
the vacuolar sequestration of amiodarone occurs at con-
centrations close to therapeutic levels. It is mediated by
V-ATPase and evolves toward persistent macroautophagy
and phospholipidosis. In case of discontinuation of amio-
darone complete relief of symptoms can be expected.
Amiodarone-induced pulmonary mass is very rarely
reported in adults and according to Labombarda F et al.
[8], is extremely rare in children. Basically it is thought to
represent a subtype of the rather common phenomenon
of amiodarone-induced pulmonary toxicity (AIPT). Fac-
chini and colleagues reported that amiodarone can dam-
age the lung via an indirect immune reaction or direct
cytotoxic damage [9]. The different mechanisms of injury
contribute to the variability of symptoms onset, ranging
from 1 to 6 months. Typically AIPT presents as infiltra-
tion of the pulmonary interstitium with inflammatory
cells, interstitial fibrosis, and hyperplasia of type II pneu-
Figure 1. Demonstrating the patient’s blue-gray skin pigmentation.
(A) (B)
Figure 2. A: Chest X- ray showing nodular pulmonary infiltration. B: Computer tomography showing the nodular lesions with the aspect of
abscess forming pneumonia.
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mocytes. On biopsy, the presence of foamy macrophages
confirms exposure to amiodarone. While AIPT mostly
appears as diffuse parenchymal infiltration, the occurrence
of amiodarone-induced pulmonary mass is thought to be
due to a selective accumulation of the drug in a prior
lung lesion [10]. As reported in literature, patients with
amiodarone-induced pulmonary mass typically present
with dyspnea, cough, and fever, which can easily be mis-
taken as symptoms of pneumonia. Most patients respond
well to withdrawal of amiodarone and prednisolone can
be added to promote healing.
After all, the adverse effects of amiodarone are rarely
seen in pediatric patients. This may be due to the fact
that amiodarone is mainly used for the acute treatment of
arrhythmias, for example in the postoperative setting. But
even if amiodarone is used in the outpatient setting to
treat for example supraventricular arrhythmias in infants,
there is a substantial number of patients who expect
spontaneous disappearance of their arrhythmia and treat-
ment is only needed for a time period of months in con-
trast to the long-term treatment of atrial fibrillation or
ventricular arrhythmias in adults that often require treat-
ment for several years. Nevertheless, adverse effects similar
to those reported in adults can be seen in children if
amiodarone is applied for long-term treatment. Conse-
quently, close monitoring of possible adverse effects, early
dose reduction in amiodarone and effective sun protec-
tion of exposed regions are of particular importance to
prevent adverse effects of long-term amiodarone treat-
ment in children. As there currently exists a wide range
of effective antiarrhythmic drugs for children available on
the market, alternative substances should always be con-
sidered if a long-term treatment is expected [1].
Conclusion
Long-term administration of amiodarone can cause severe
side effects in children even if an approved dosage is pre-
scribed. Close monitoring of possible adverse effects, early
dose reduction of amiodarone and effective sun protec-
tion of exposed regions may prevent adverse effects of
long-term amiodarone treatment. The use of alternative
substances should be considered.
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